Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$15.60MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Scott Plesha
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 92
- Beta
- 3.05
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -1.89
Financials
PTHS has only 11 quarterly periods on file — the charts below show the full history available.
Revenue
$15.60M+110.7%Net Income
$-23.42MEBITDA
$-15.93MFree Cash Flow
$-7.67MEPS (diluted)
$-6.62Shares Outstanding (diluted)
3.54M+502.2%Operating Expenses
$28.00MCash & Debt
$24.56MReturn of Capital
$0.00Revenue by Segment (annual)
$589.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $16.80M | $-43.32M | $-23.04 |
| 2024 | $0.00 | $-7.96M | $-13.54 |
| 2023 | $0.00 | $-7.38M | $-12.80 |
| 2022 | $0.00 | $-2.46M | $-4.26 |
| 2021 | $0.00 | $-595.4K | $-1.00 |
| 2020 | $199.9K | $-660.6K | $-1.15 |
Valuation
PTHShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-50.00%Social Signal Score
Mentions (3)
- Newsmarketbeat.com·53d ago·Positive
Pelthos Therapeutics Q2 Earnings Call Highlights Pelthos Therapeutics NYSEAMERICAN: PTHS reported second-quarter revenue growth as prescriptions for its lead product, ZELSUVMI, increased following the treatment's July 2025 commercial launch. The company also discussed an accounting restatement related to the fair-value measurement of convertible debt and outlined expected 2027 launches for its complementary products XEPI and XEGLYZE.
View source ↗ - Newszacks.com·54d ago·Negative
Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $6.62 per share versus the Zacks Consensus Estimate of a loss of $3.02. This compares to a loss of $5.38 per share a year ago.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results Zelsuvmi ® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-2.90 per share
Typical surprise -42.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-6.62 vs $-2.82miss
- Thu, May 14$-3.09 vs $-3.45beat
- Thu, Mar 19$-6.87 vs $-3.95miss
- Thu, Nov 13$-5.30 vs $-0.67miss
- Wed, Aug 13$-5.38 vs $-5.82beat
- Tue, May 13$-3.21 vs $-2.90miss
Estimates and results for PTHS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PTHS officers and directors.
- Bought
- $1.4m
- Sold
- $441k
3 trades
21 trades
- Friedberg Ezra Msold
- Friedberg Ezra Msold
- Pauls Matthewsold
- Pauls Matthewsold
- Greenleaf Petersold
- Greenleaf Petersold
- Friedberg Ezra Msold
- Friedberg Ezra Msold
66 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PTHS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.